UroGen Pharma Stock Quote URGN - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

16.66

Bid

16.40

Ask

16.65

Volume

366,104

15.952 Day's Range 16.67

8.69 52 Week Range 24.13

Market Cap

581.695M

Previous Close

16.10

Open

16.06

Last Trade

16.69

Last Trade Time

Financial Volume

$ 5,956,399

VWAP

16.2697

Average Volume (3m)

627,282

Shares Outstanding

36,130,121

Dividend Yield

PE Ratio

-5.89

Earnings Per Share (EPS)

-2.83

Revenue

82.71M

Net Profit

-102.24M

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment opt... UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.urogen.com

Headquarters

Ra'anana, Center, Isr

Founded

1970

UroGen Pharma Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker URGN. The last closing price for UroGen Pharma was $16.10. Over the last year, UroGen Pharma shares have traded in a share price range of $ 8.69 to $ 24.13.

UroGen Pharma currently has 36,130,121 shares outstanding. The market capitalization of UroGen Pharma is $581.69 million. UroGen Pharma has a price to earnings ratio (PE ratio) of -5.89.

UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Kaplan-Meier Estimate of Duration of Response at 12 Months in Patients Who Achieved a Complete Response at Three Months was 82.3% (95% CI, 75.9%, 87.1%) Side Effect Profile Consistent with...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.24	1.46163215591	16.42	16.67	14.89	417773	15.49519705	CS
4	3.89	30.4620203602	12.77	20.7	12.3	1379105	17.00778944	CS
12	1.985	13.5264054514	14.675	20.7	10.6001	627282	15.93890611	CS
26	2.26	15.6944444444	14.4	20.7	10.6001	480241	16.05784188	CS
52	5.56	50.0900900901	11.1	24.13	8.69	465193	16.57979402	CS
156	1.66	11.0666666667	15	24.13	4.85	242493	14.30563784	CS
260	-17.44	-51.1436950147	34.1	36.72	4.85	219358	17.70032273	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SNGXSoligenix Inc	$ 7.42 (271.00%)	134.15M
ZAPPZapp Electric Vehicles Group Ltd	$ 17.9001 (93.72%)	45.51M
PEGYPineapple Energy Inc	$ 2.30 (91.67%)	77.57M
ATNF180 Life Sciences Corporation	$ 2.9017 (79.12%)	31.21M
QUREuniQure NV	$ 6.65 (75.93%)	51.5M
NVOSNovo Integrated Sciences Inc	$ 0.4874 (-35.44%)	3.12M
FAASDigiAsia Corporation	$ 3.65 (-34.17%)	49.17k
INDVIndivior PLC	$ 10.18 (-33.64%)	2.95M
CLEUChina Liberal Education Holdings Ltd	$ 0.3905 (-31.59%)	9.24M
HUBCWHub Cyber Security Ltd	$ 0.0165 (-31.25%)	1.9k
NVDANVIDIA Corporation	$ 131.38 (2.48%)	287.04M
MAXNMaxeon Solar Technologies Ltd	$ 0.2451 (-9.22%)	233.68M
TSLATesla Inc	$ 262.33 (3.71%)	160.74M
SNGXSoligenix Inc	$ 7.42 (271.00%)	134.15M
INTCIntel Corporation	$ 34.59 (1.77%)	97.81M